EGFR and non-small cell lung carcinoma: NSCLC patients with EGFR exon 20 insertion mutations that were enrolled into the phase I CHRYSALIS study (NCT02609776) were treated with amivantamab intravenously once weekly for the first cycle (28 days) and once every 2 weeks for subsequent 28-day cycles, starting at week 5 [63].